Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.73 |
| ▸ | MKNK1 | Q9BUB5 | 12/20 | 0.70 |
| ▸ | MKNK2 | Q9HBH9 | 12/20 | 0.70 |
| ▸ | F7 | P08709 | 1/20 | 0.65 |
| ▸ | F3 | P13726 | 1/20 | 0.65 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.65 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.65 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.65 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.65 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.65 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30037096 | 0.98 | KMO (0.71) | KMOMKNK1MKNK2F7F3 | |
| SCHEMBL13188346 | 0.86 | MKNK1 (0.77) | KMOMKNK1MKNK2F7F3 | |
| SCHEMBL30108236 | 0.86 | MKNK1 (0.77) | KMOMKNK1MKNK2F7F3 | |
| SCHEMBL27605046 | 0.86 | KMO (0.77) | KMOMKNK1MKNK2SIRT2MEN1 | |
| SCHEMBL29569537 | 0.84 | KMO (1.00) | KMOMKNK1MKNK2PIM1MEN1 | |
| SCHEMBL28297133 | 0.84 | KMO (1.00) | KMOMKNK1MKNK2PIM1MEN1 | |
| SCHEMBL206541 | 0.84 | KMO (1.00) | KMOMKNK1MKNK2PIM1MEN1 | |
| SCHEMBL3661330 | 0.84 | CCNT1 (0.52) | KMOMKNK1MKNK2F7F3 | |
| SCHEMBL30114603 | 0.84 | KMO (0.65) | KMOMKNK1MKNK2F7F3 | |
| SCHEMBL4508905 | 0.84 | MKNK1 (0.71) | KMOMKNK1MKNK2F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102153539-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP | 2011-08-17 | — | — | CN | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1919875-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | Astex Therapeutics Limited (GB) | 2008-05-14 | — | — | EP | claimed |
| WO-2006136829-A2 | PYRAZOLE DERIVATIVES AND THEIR USE AS PKA AND PKB MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| US-20060276453-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | claimed |
| WO-2024080780-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-04-18 | — | — | WO | disclosed |
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2017-07-13 | — | — | US | disclosed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | disclosed |
| US-20030008867-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | KMO 3770/4885MKNK1 715/4885MKNK2 933/4885 |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | KMO 499/4885MKNK1 3277/4885MKNK2 3007/4885 |
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | KMO 2842/4885MKNK1 90/4885MKNK2 94/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | KMO 3770/4885MKNK1 715/4885MKNK2 933/4885 |
| US-20030008867-A1 | Compounds | DRD2, DRD1, GRIN2A | KMO 3228/4885MKNK1 2904/4885MKNK2 2375/4885 |
| US-20060276453-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | KMO 2253/4885MKNK1 76/4885MKNK2 46/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | KMO 3770/4885MKNK1 715/4885MKNK2 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.